The potential biological and clinical significance of the soluble tumor necrosis factor receptors

Cytokine and Growth Factor Reviews

Volumn 7, Issue 3, 1996, Pages 231-240

  Aderka, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Receptor; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD; CANCER; CLINICAL TRIAL; COMMUNICABLE DISEASE; HEART MUSCLE; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; METABOLISM; MOUSE; NEOPLASM; PHYSIOLOGY; PROTEIN ANALYSIS; SEPSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLUBILITY;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; COMMUNICABLE DISEASES; HUMANS; INFLAMMATION; MICE; MYOCARDIUM; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; SEPSIS; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0030265258     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(96)00026-3     Document Type: Short Survey

References (106)

1. 1. Aggarwal BB, Natarajan, K. Tumor necrosis factor: Developments during the last decade. Eur Cytokine Netw 1996, 7, 93-124.
2. 2. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992, 13, 151-153.
3. 3. Loetscher H, Steinmetz M, Lesslauer W. Tumor necrosis factor: receptors and inhibitors. Cancer Cells 1991, 3, 221-226.
4. 4. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wacheter H, Fuchs D. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995, 54, 1-8.
5. 5. Hu FQ, Smith CA, Pickup DJ. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 1994, 204, 343-356.
6. 6. Smith CA, Davis T, Wignall JM, Din WS, Farrah T, McFadden G, Goodwin RG. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem Biophys Res Commun 1991, 176, 335-342.
7. 7. Sedger L, Schrieber M, Macen J, McFadden G. The myxoma virus TNF-receptor homologue MT2 protects lymphocytes from virus induced apoptosis. Eur Cytokine Netw 1996, 7, 272 (abstract).
8. 8. Tartaglia AT, Pennica D. Goeddel DV. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993, 268, 18542-18548.
9. 9. Bigda J, Beletsky I, Brakebusch C, Varfolomeev Y, Englemann H, Bigda J, Holtmann H, Wallach D. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med 1994, 180, 445-460.
10. 10. Englemann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989, 264, 11974-11980.
11. 11. Englemann H, Novick D, Wallach D. Two tumor necrosis factor binding proteins purified from human urine. J Biol Chem 1990, 265, 1531-1536.
12. 12. Seckinger P, Issaz S, Dayer JM. Purification and biologic activity of a specific tumor necrosis factor a inhibitor. J Biol Chem 1989, 264, 11966-11973.
13. 13. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989, 42, 270-275.
14. 14. Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, Holtmann H, Wallach D. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990, 9, 3269-3278.
15. 15. Lantz M, Malik S, Slevin M, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990, 2, 402-406.
16. 16. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin 6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83, 113-118.
17. 17. Bargetzi MJ, Lanta M, Smith CG, Torti FM, Olsson I, Eisenberg SP, Starnes HF. Interleukin-1 beta induces interleukin-1 antagonist and tumor necrosis factor binding protein in humans. Cancer Res 1993, 53, 4010-4013.
18. 18. Miles DW, Aderka D, Englemann H, Wallach D, Balkwill FR. Induction of soluble tumor necrosis factor receptors during treatment with interleukin-2. Br J Cancer 1992, 66, 1195-1199.
19. 19. Aderka D, Englemann H, Wallach D. Soluble tumor necrosis factor receptors in health and disease. In Friers W, Buurman WA, eds. Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Karger, Basel, 1993, 191-198.
20. 20. Totpal K, Chaturvedi MM, Pushin RE, Aggarwal BB. Retinoids down regulate both p60 and p80 form of tumor necrosis factor receptors in humans histiocytic lymphoma U-937 cells Blood 1995, 85, 3547-3555.
21. 21. Björnberg F, Lantz M. Endothelial cell contact potentiates the proteolytic release of soluble TNF-R75-BP from monocyte-like cell line THP-1. Eur Cytokine Netw 1966, 7, 161 (abstract).
22. 22. Lantz M, Björnberg F, Olsson I, Richter J. Adherence of neutrophils induces release of soluble tumor necrosis factor receptors forms. J Immunol 1994, 152, 1362-1369.
23. 23. Cope AP, Aderka D, Wallach D, Kahan M, Chu NR, Brennan FM, Feldman M. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunol 1995, 84, 21-30.
24. 24. Aderka D, Sorkine P, Setton A, Lev D, Cope AP, Bigda J, Klausner J, Wallach D. Kinetics of TN F receptor (TNF-R) shedding in vivo in response to TNF and other cytokines compared to their shedding in cancer patients treated with TNF by isolated limb perfusion. Eur Cytokine Netw 1994, 5, 191 (abstract).
25. 25. Porteu F, Brockhaus M, Wallach D, Englemann H, Nathan CF. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. J Biol Chem 1991, 266, 18846-18853.
26. 26. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kDa TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995, 181, 1205-1210.
27. 27. Mullberg J, Durie F, Otten-Evans C, Alderson MR, Roseholn S, Cosman D, Black RA, Mohler KM. A metalloproteinase inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995, 155, 5198-5205.
28. 28. Brennan FM, Williams L, Gibbons DL, Maini RN, Feldmann M. Paradoxical effects of a synthetic metalloproteinase inhibitor which blocks both p55 and p75 TNF receptor shedding and TNF-α processing in RA synovial membrane cell cultures. Eur Cytokine Netw 1996, 7, 252 (abstract).
29. 29. Black R, Rauch C, Kozlosky C, Wolfson M, Castner B, Reddy P, Davis R, Peschon J, Slack J, Gerhart M, Paxton R, March C, Cerretti D. Cloning of a membrane-bound TNF-a converting enzyme (TACE). Eur Cytokine Netw 1996, 7, 180 (abstract).
30. 30. Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991, 51, 5602-5607.
31. 31. Petersen MC, Nykjoer A, Christiansen BS, Heickenporff L, Morgensen SC, Moler B. Bioactive human recombinant tumor necrosis factor alpha: an unstable dimer? Eur J Immunol 1989, 19, 1887-1891.
32. 32. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175, 323-329.
33. 33. De Groote D, Grau GE, Dehart I, Franchimont P. Stabilization of functional tumor necrosis factor-a by its soluble receptors. Eur Cytokine Netw 1993, 4, 359-362.
34. 34. Beutler B, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production distribution and metabolic fate in vivo. J Immunol 1985, 135, 3972-3977.
35. 35. Gascon M-P, Porchet HC, Le Contonnec J-Y, Ythier A, Wallach D, Piguet P-F, Grau GE. Pharmacokinetics and tissue distribution of human urinary tumor necrosis factor binding protein in mice. Drug Metab Disposition 1992, 20, 592-595.
36. 36. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151, 1548-1561.
37. 37. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991, 174, 1483-1489.
38. 38. Evans TJ, Moyes D, Carpenter A, Martin R, Loestcher H, Lesslauer W, Cohen J. Protective effect of 55 but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. J Exp Med 1994, 180, 2173-2179.
39. 39. Ashkenazi A, Masters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesion. Proc Natl Acad Sci USA 1991, 88, 10535-10539.
40. 40. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet P-F, Pointaire P, Vassalli P, Loestsscher H. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991, 21, 2883-2886.
41. 41. Aderka D, Engelmann H. Shemer-Avni I, Hornik V, Galil A, Sarov B, Wallach D. Variation in serum levels of the soluble TNF receptors among healthy individuals, Lymphokine Cytokine Res 1992, 10, 157-159.
42. 42. Tur-Kaspa I, Maor Y, Weissenberg R. Madgar I, Aderka D, Dor J, Mashiach S, Wallach D. High levels of soluble p55-TNF receptors in seminal and prostatic fluids of normal and infertile men. J Urology 1996, 155, 1436-1438.
43. 43. Sherwood ER, Ford TR, Lee C, Kozlowski JM. Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J Biol Response Mod 1990, 9, 44-52.
44. 44. Opsjn S-L, Novick D, Wathen NC, Cope AP, Wallach D, Aderka D. Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies. J Reprod Immunol 1995, 29, 119-134.
45. 45. Opsjn S-L, Wathen NC, Tingulstad S, Wiedswang G, Sudan A, Waage A, Augustulen R. Tumor necrosis factor, interleukin-1 and interleukin-6 in normal human pregnancy. Am J Obstet Gynecol 1993, 169, 397-404.
46. 46. Aderka D, Granot V, Levavi H, Levo Y, Wallach D. The value of soluble TNF receptors in predicting relapse of ovarian carcinoma. Eur Cytokine Netw 1994, 5, 217 (abstract).
47. 47. Black PH. Shedding from the surfaces of normal and cancer cells. Adv Cancer Res 1980, 32, 75-199.
48. 48. Beissert S, Bergholz M, Waase I, Lepsien G, Schauer A, Pfizenmaier K, Krönke M. Regulation of tumor necrosis factor expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci USA 1989, 86, 5064-5068.
49. 49. Spriggs DR, Imamura K, Rodriguez C, Sariban E, Kufe DW. Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest 1988, 81, 455-460.
50. 50. Naylor S, Malik STA, Stamp GWH, Jobling T, Balkwill FR. In situ detection of tumor necrosis factor in human ovarian cancer specimens. Eur J Cancer 1990, 26, 1027-1030.
51. 51. Liabakk NB, Sudan A, Espevik T. CD14 is involved in tumor cell-induced production of TNF from monocytes. Eur Cytokine Netw 1996, 7, 189 (abstract).
52. 52. Janicke R. Mannel DM. Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis. J Immunol 1990, 114, 1144-1150.
53. 53. Vilcek J, Palombella VJ, Henriksen-DeStefano D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986, 163, 632-643.
54. 54. Frater-Schröder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987, 84, 5277-5281.
55. 55. Leibrovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor alpha. Nature (Lond) 1987, 329, 630-632.
56. 56. Dayer JM, Beutler B, Cerami AJ. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985, 162, 2163-2168.
57. 57. Lee TH, Lee GW, Ziff EB, Vilcek J. Isolation and characterisation of eight tumor necrosis factor induced gene sequences from human fibroblasts. Mol Cell Biol 1990, 10, 1982.
58. 58. Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinase and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS 1990, 269, 93.
59. 59. Malik STA, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int J Cancer 1989, 44, 918-925.
60. 60. Malik STA, Naylor MS, East N, Oliff A, Balkwill FR. Cells secreting tumor necrosis factor show enhanced metastasis in mice. Eur J Cancer 1990, 26, 1031-1034.
61. 61. Rice GE, Gimborne MA, Bevilacqua MP. Tumor cell endothelial interactions. Increased adhesion of human melanoma cells to activated vascular endothelium. Am J Pathol 1988, 133, 204.
62. 62. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer MJ. Imbalance between TNFa and soluble TNF receptor concentrations in severe meningococcemia. Immunol 1994, 76, 20-23.
63. 63. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk E, Allred R, Pennington JE, Wherry JC. Efficacy and safety of a monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: A randomized, controlled, double blind, multicenter clinical trial. JAMA 1995, 273, 934-941.
64. 64. Echtenacher B, Falk W, Manne DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990, 145, 3762-3766.
65. 65. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991, 163, 83-88.
66. 66. Kaul M, Eiselstein J. Kempeni J, Daum L. TNF neutralization in sepsis guided by IL-6 serum levels. Eur Cytokine Netw 1996, 7, 283 (abstract).
67. 67. Leighton A, Abraham E, Glauser M, Passe S, Bock J. Kneer J, Dumont E, Maladorno D, Zwingelstein C, Dahlström C, Lesslauer W. TNF-R55-IgG1 (Ro-45-2081) in severe sepsis shock: Rationale for design of the phase III protocol. Eur Cytokine Netw 1996, 7, 282 (abstract).
68. 68. Suffredini AF. Anticytokine therapies In: Natanson C, ed Moderator. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994, 120, 771-783.
69. 69. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Araham E, Schein RMD, Benjamin E. For the soluble TNF receptor sepsis study group. Treatment of septic shock with tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996, 334, 1697-1702.
70. 70. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in humans immunodeficiency virus type I infection. Correlations to clinical immunologic and virologic parameters. J Infect Dis 1994, 169, 420-424.
71. 71. Zangerle R, Gallarti H, Sarcletti M, Wachter H, Fuchs D. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. Immunol Lett 1994, 41, 229-234.
72. 72. Godfried MH, Van der Poll T, Weeverling GJ, Mulder JW, Jansen J, van-Deventer SJ, Sauerwein HP. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type I infection. J Infect Dis 1994, 169, 739-745.
73. 73. Zangerle R, Fuchs D, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Dierich MP, Most J. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+lymphocytes in HIV. Infection Clin Immunol Immunopathol 1994, 72, 328-334.
74. 74. Keuter M, Dharmana E, Gasem MH, van der Ven-Jongekrijg J, Djokomoeljanto R, Dolmans WM, Demacker P, Saurrwein R, Gallati H, van-der Meer JW. Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J Infect Dis 1994, 169, 1306-1311.
75. 75. Kern P, Hemmer CJ, Gallati H, Neifer S, Kremsner P, Dietrich M, Porzsolt F. Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis 1992, 166, 930-934.
76. 76. Kern WV, Engel A, Schieffer S, Prummer O, Kern P. Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis. Infect Immun 1993, 61, 5413-5416.
77. 77. Zijlstra EE, van-der Poll T, Mevissen M. Soluble receptors for tumor necrosis factor as markers of disease activity in visceral leishmaniasis. J Infect Dis 1995, 171, 498-501.
78. 78. Steinshamn S, Brekke OL, Waage A. Soluble tumor necrosis factor receptors, tumor necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever. Br J Haematol 1995, 89, 719-724.
79. 79. Aderka D, Wysenbeek AJ. Cope A, Englemann H, Molad Y, Hornick V, Levo Y, Feldmann M, Wallach D. Circulating soluble receptors for tumor necrosis factor (TNF) in systemic lupus erythematosus mirror disease activity. Arthr Rheum 1993, 36, 1111-1120.
80. 80. Cope AP, Aderka D, Doherty M, Englemann H, Gibbons D, Jones A, Brennan MF, Maini RN, Wallach D, Feldmann M. Soluble tumor necrosis factor (TNF) receptors are upregulated in the sera and synovial fluids of patients with rheumatic diseases. Arthr Rheum 1992, 35, 1160-1169.
81. 81. Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallatio H, Guerne P-A, Dayer J-M. Soluble tumor necrosis factor in human inflammatory synovial fluids. Arthr Rheum 1993, 36, 485-489.
82. 82. Elliot MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC. Macfarlane JD, Biji H. Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344, 1105-1110.
83. 83. Eliaz R, Wallach D, Kost J. Long lasting protection against tumor necrosis factor (TNF) effects by controlled delivery of the soluble form of the p55 TNF receptor. Eur Cytokine Netw 1966, 7, 291 (abstract).
84. 84. Bragger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 329, 89-91.
85. 85. MacDonald TT, Hutchings P, Choy M, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990, 81, 301-305.
86. 86. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio PWS, MacDonald TT. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994, 106, 1455-1466.
87. 87. van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109, 129-135.
88. 88. Rydberg J, Miorner H, Chandramuki A, Lantz M. Assessment of a possible imbalance between tumor necrosis factor (TNF) and soluble TNF receptor forms in tuberulous infection of the central nervous system. J Infect Dis 1995, 172, 301-304.
89. 89. Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor during acute Kawasaki disease. J Pediatr 1994, 124, 721-725.
90. 90. Tilg H, Vogel W, Wiedermann CJ, Shapiro L, Herold M, Judmair G. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease. Hepatology 1993, 18, 1132-1138.
91. 91. Hsu MM, Ko JY, Chang YL. Elevated levels of soluble interleukin-2 receptor and tumor necrosis factor in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1991, 117, 1257-1259.
92. 92. Zoumbos N, Symeonidis A, Kourakli A, Katevas P, Mastouka P, Perraki M, Georgoulias V. Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes. Blood 1991, 77, 413-414.
93. 93. Trentin L, Pizzolo F, Zambello R, Agostini C, Morosato L, Sancetta R, Adami F, Vinante F, Chilosi M, Gallati H. Leukaemic cells in hairy cell leukaemia and B cell chronic lymphocytic leukaemia release soluble TNF receptors. Leukaemia 1995, 9, 1051-1055.
94. 94. Samsonov MY, Tilz GP, Pisklakov VP, Reibnegger G, Nassonov EL, Nassonov VA, Wachter H, Fuchs D. Serum soluble receptors for tumor necrosis factor alpha and interleukin-2, and neopterin in acute rheumatic fever. Clin Immunol Immunopathol 1995, 74, 31-34.
95. 95. Mangge H, Kenzian W, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, Beaufort F, Muntean W, Schauenstein K. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthr Rheum 1995, 38, 211-220.
96. 96. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumor necrosis factor alpha biological activity in oseriatic skin lesions. Clin Exp Immunol 1994, 96, 146-151.
97. 97. Tan LR, Waxman K, Sannell G, Ioli G, Granger GA. Trauma causes early release of soluble receptors for tumor necrosis factor. J Trauma 1993, 34, 634-638.
98. 98. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995, 92, 1479-1486.
99. 99. Saatvedt K, Lindberg H, Geriran OR, Michelsen S, Aasen AO, Pedersen T, Mollnes TE. Complement activation and release of tumor necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumor necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scand J Clin Lab Invest 1995, 55, 79-86.
100. 100. Latini R, Bianchi M, Correale E, et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994, 23, 1-6.
101. 101. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, Pflughaupt KW, Toyka KV. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imagining. Ann Neurol 1995, 38, 186-193.
102. 102. Chasty RC, Lamb WR, Gallati H, Roberts TE, Brenchley PE, Yin JA. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993, 12, 331-336.
103. 103. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 1990, 323, 236-241.
104. 104. Cunnion RE. Myocardial depressant substance (pp. 237-239 in Parrillo JE Moderator. Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy). Ann Intern Med 1990, 113, 227-242.
105. 105. DeMeules JE, Pigula FA, Mueller M, Raymond SJ, Gamelli RL. Tumor necrosis factor and cardiac function. J Trauma 1992, 32, 686-692.
106. 106. Heilig B, Fiehn C, Brockhaus M, Galatti H, Pezzutto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis and mixed connective tissue disease. J Clin Immunol 1993, 13, 321-328.